QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
Log in
NASDAQ:IDXG

Interpace Biosciences Stock Forecast, Price & News

$3.03
+0.01 (+0.33 %)
(As of 11/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.00
Now: $3.03
$3.14
50-Day Range
$2.88
MA: $3.32
$4.34
52-Week Range
$2.57
Now: $3.03
$11.00
Volume43,018 shs
Average Volume420,933 shs
Market Capitalization$12.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Read More
Interpace Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:IDXG
CUSIP69329V10
Phone855-776-6419
Employees176

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.08 million
Book Value$3.41 per share

Profitability

Net Income$-26,730,000.00
Net Margins-115.30%

Miscellaneous

Market Cap$12.25 million
Next Earnings Date11/25/2020 (Estimated)
OptionableNot Optionable
$3.03
+0.01 (+0.33 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Interpace Biosciences (NASDAQ:IDXG) Frequently Asked Questions

How has Interpace Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Interpace Biosciences' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IDXG shares have decreased by 53.1% and is now trading at $3.03.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Interpace Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Interpace Biosciences
.

What stocks does MarketBeat like better than Interpace Biosciences?

Wall Street analysts have given Interpace Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Interpace Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Interpace Biosciences' next earnings date?

Interpace Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 25th 2020.
View our earnings forecast for Interpace Biosciences
.

How were Interpace Biosciences' earnings last quarter?

Interpace Biosciences, Inc. (NASDAQ:IDXG) released its quarterly earnings data on Monday, October, 19th. The business services provider reported ($1.35) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.48) by $0.13. Interpace Biosciences had a negative return on equity of 251.52% and a negative net margin of 115.30%.
View Interpace Biosciences' earnings history
.

What guidance has Interpace Biosciences issued on next quarter's earnings?

Interpace Biosciences issued an update on its third quarter 2020 IntraDay earnings guidance on Tuesday, October, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.5-7.8 million, compared to the consensus revenue estimate of $8.4 million.

What price target have analysts set for IDXG?

4 brokerages have issued twelve-month price targets for Interpace Biosciences' stock. Their forecasts range from $7.00 to $12.00. On average, they expect Interpace Biosciences' share price to reach $9.67 in the next twelve months. This suggests a possible upside of 219.0% from the stock's current price.
View analysts' price targets for Interpace Biosciences
.

Who are some of Interpace Biosciences' key competitors?

What other stocks do shareholders of Interpace Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD).

Who are Interpace Biosciences' key executives?

Interpace Biosciences' management team includes the following people:
  • Mr. Jack E. Stover, CEO, Pres & Director (Age 67, Pay $475.05k)
  • Mr. Gregory Richard, Sr. VP & Chief Commercial Officer of Interpace Diagnostics (Age 53, Pay $320.55k)
  • Mr. Fred S. Knechtel, CFO, Treasurer & Company Sec. (Age 59)
  • Mr. Thomas John Freeburg, Chief Accounting Officer (Age 52)
  • Dr. Sydney D. Finkelstein, Chief Scientific Officer
  • Dr. Alidad Mireskandari Ph.D., Sr. VP of Bus. Devel.
  • Mr. Patrick Kane, VP & Corp. Controller

What is Interpace Biosciences' stock symbol?

Interpace Biosciences trades on the NASDAQ under the ticker symbol "IDXG."

Who are Interpace Biosciences' major shareholders?

Interpace Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (7.04%), Magnus Financial Group LLC (1.20%) and Squarepoint Ops LLC (0.62%).
View institutional ownership trends for Interpace Biosciences
.

Which institutional investors are buying Interpace Biosciences stock?

IDXG stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Magnus Financial Group LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for Interpace Biosciences
.

How do I buy shares of Interpace Biosciences?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Interpace Biosciences' stock price today?

One share of IDXG stock can currently be purchased for approximately $3.03.

How big of a company is Interpace Biosciences?

Interpace Biosciences has a market capitalization of $12.25 million and generates $24.08 million in revenue each year. The business services provider earns $-26,730,000.00 in net income (profit) each year or ($5.58) on an earnings per share basis. Interpace Biosciences employs 176 workers across the globe.

What is Interpace Biosciences' official website?

The official website for Interpace Biosciences is www.interpace.com.

How can I contact Interpace Biosciences?

Interpace Biosciences' mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.